2 Dividend Stocks Built to Hold Up When Markets Don't

The article highlights Johnson & Johnson and AbbVie as defensive dividend holdings amid concerns over Iran-related oil prices, U.S. inflation, and AI spending. J&J is targeting more than $100 billion in annual revenue and pays a $5.36 per-share dividend yielding 1.9%, while AbbVie posted 10% quarterly revenue growth to more than $16 billion and pays $6.92 per share, yielding 2.7%. AbbVie's Skyrizi and Rinvoq each grew about 24%, helping offset Humira's post-exclusivity sales decline.

Analysis

This is not a new fundamental catalyst; it is a defensive-allocation prompt. The relevant relative-value question is whether ABBV and JNJ can preserve earnings revisions if inflation and oil reaccelerate while long-duration AI equities de-rate. JNJ’s diversified pharma/medtech mix should have lower single-asset concentration risk, while ABBV offers greater income carry but materially higher dependence on continued immunology execution to offset legacy-product erosion. In a risk-off rotation, the likely first-order beneficiaries are large-cap healthcare ETFs (XLV, IYH), but passive flows may favor JNJ given its index weight and lower perceived pipeline risk.

ABBV’s upside over the next 6-18 months depends on whether Skyrizi/Rinvoq growth remains sufficient to support consensus earnings growth after promotional spending, acquisitions, and aesthetics normalization. A slowdown in dermatology or a weaker elective-procedure environment would expose the market’s willingness to pay for ABBV’s higher yield. For JNJ, the more consequential risks are litigation reserve developments, drug-pricing policy implementation, and oncology pipeline readouts; revenue scale alone does not prevent multiple compression if capital allocation or legal liabilities worsen.

Contrarian view: dividend durability is often overvalued when bond yields are rising. If real yields move materially higher, both names can underperform despite defensive earnings because their valuation support competes directly with Treasuries. The cleaner expression is therefore not outright “buy dividends,” but owning healthcare earnings resilience against cyclically exposed sectors with greater input-cost and demand sensitivity.

Key Decisions for Investors

• Watch, do not chase, JNJ on generic defensive flows. Initiate only after confirming stable innovative-medicine guidance and no adverse litigation-reserve revision; target a 6-12 month long versus short XLI or XLY, where higher energy and rates pressure cyclical margins and discretionary demand.
• Prefer ABBV over JNJ only if quarterly Skyrizi plus Rinvoq growth remains above consensus and management reiterates full-year immunology guidance. Use a 3-6 month ABBV/JNJ pair long for higher carry and growth; exit if immunology growth decelerates materially or aesthetics guidance is cut.
• For broad risk-off positioning, use a modest long XLV versus short XLY rather than concentrated single-name exposure. The trade has a clearer macro transmission mechanism over the next 1-3 months if inflation surprises higher; invalidate on falling real yields and improving discretionary-sales revisions.
• Set a rate trigger: if the 10-year real yield rises by roughly 40-50bp from entry, reduce healthcare-dividend exposure rather than adding. Multiple compression can overwhelm dividend carry, particularly for ABBV.